Allergan gets Canadian right to Sanctura

Indevus Pharmaceuticals has signed a license agreement with the Canadian affiliate of USA-based Allergan, granting the firm the right to market Sanctura XR (trospium chloride extended release preparation) throughout Canada. Indevus jointly granted the rights along with Rottapharm Madaus, the Italian firm which originally developed the product, as required by a prior agreement between the two latter companies.

Indevus and Rottapharm Madaus will share equally in the proceeds from the license transaction. Under the terms of the deal, Allergan will pay up to $9.0 million to each of Indevus and Rottapharm Madaus, including a $7.0-million up-front license fee and up to $2.0 million in sales threshold milestone payments. Allergan will be responsible for all regulatory and marketing activities in Canada.